



University of Groningen

Catalytic asymmetric conjugate addition of dialkylzinc reagents to alpha, beta-unsaturated sulfones

Bos, Pieter H.; Macia, Beatriz; Fernandez-Ibanez, M. Angeles; Minnaard, Adriaan J.; Feringa, Ben L.

Published in: Organic & Biomolecular Chemistry

DOI: 10.1039/b917269f

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2010

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Bos, P. H., Macia, B., Fernandez-Ibanez, M. A., Minnaard, A. J., & Feringa, B. L. (2010). Catalytic asymmetric conjugate addition of dialkylzinc reagents to alpha,beta-unsaturated sulfones. *Organic & Biomolecular Chemistry*, *8*(1), 47-49. https://doi.org/10.1039/b917269f

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Supporting Information

Catalytic Asymmetric Conjugate Addition of Diorganozinc Reagents to α , β -Unsaturated Sulfones

Pieter H. Bos, Beatriz Maciá, M. Ángeles Fernández-Ibáñez, Adriaan J. Minnaard and Ben L. Feringa*

The Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG Groningen

Table of Contents	S2 S3 S4
General Information Experimental section Synthesis of methyl 2-pyridyl sulfone General procedure for the synthesis of α , β -unsaturated sulfones General procedure for the conjugate addition of diorganozinc reagents to α , β -unsaturated sulfones	
	S5
	S 9
	NMR spectra of new compounds

General Information:

All reactions were carried out under a nitrogen atmosphere using flame dried glassware. Toluene was distilled over sodium. All solvents were stored under nitrogen atmosphere. All copper-salts were purchased from Aldrich or Acros and used without further purification. Diorganozinc reagents were purchased from Aldrich [Me₂Zn (2.0 M in toluene), Et₂Zn (1.0 M in hexane), *i*-Pr₂Zn (1.0M in toluene), Bu₂Zn (1.0 M in heptane), Ph₂Zn (solid)]. Racemic 1,4-addition products were synthesized by reaction of the α , β -unsaturated sulfones (3) with the corresponding Grignard reagent (1.2 eq) at –20 °C in THF in the presence of Cul (1.5 eq).

Chromatography: Merck silica gel type 9385 230-400 mesh, TLC: Merck silica gel 60, 0.25 mm. Components were visualized by staining with a solution of a mixture of KMnO₄ (10 g) and K₂CO₃ (10 g) in H₂O (500 mL). Progress and conversion of the reaction were determined by GC-MS (GC, HP6890: MS HP5973) with an HP1 or HP5 column (Agilent Technologies, Palo Alto, CA). Mass spectra were recorded on a AEI-MS-902 mass spectrometer (EI+), a LTQ Orbitrap XL (ESI+) or an Applied Biosystems Q-Star XL mass spectrometer. ¹Hand ¹³C-NMR were recorded on a Varian AMX400 (400 and 100.59 MHz, respectively) or a Varian VXR300 (300 and 75 MHz, respectively) using CDCl₃ as solvent. Chemical shift values are reported in ppm with the solvent resonance as the internal standard (CHCl₃: δ 7.26 for ¹H, CDCl₃: δ 77.0 for ¹³C). Data are reported as follows: chemical shifts, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants (Hz), and integration. Optical rotations were measured on a Schmidt + Haensch polarimeter (Polartronic MH8) with a 10 cm cell (c given in g/100 mL). Enantioselectivities were determined by HPLC analysis using a Shimadzu LC-10ADVP HPLC equipped with a Shimadzu SPD-M10AVP diode array detector. Melting points were measured using a Büchi Melting Point B-545.

Experimental Section:

Synthesis of methyl 2-pyridyl sulfone¹



To a solution of 2-mercaptopyridine (11.11 g, 100 mmol) in dry THF (200 mL) and CH₃CN (20 mL), cooled to 0 °C, was added DBU (16.75 g, 110 mmol). The resulting mixture was stirred at 0 °C for 5 min before MeI (15.61 g, 110 mmol) was slowly added. The ice bath was removed and the mixture was stirred overnight. The reaction mixture was washed with water (100 mL) and the aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organic layers were dried (MgSO₄), filtered and concentrated. The residue was purified by flash chromatography (*n*-hexane-EtOAc 2:1) to afford the methyl 2-pyridyl sulfide (**A**) as a colorless oil; yield: 12.26 g (98%). ¹H-NMR (300 MHz): δ 8.42 (m, 1H), 7.47 (m, 1H), 7.16 (m, 1H), 6.96 (m, 1H), 2.55 (s, 3H). ¹³C-NMR (75 MHz): δ 159.9, 149.3, 135.6, 121.3, 119.0, 13.1.

To a solution of **A** (12.26 g, 98 mmol) in EtOAc (125 mL) was added H₂O (15 mL) and Na₂WO₄·2H₂O (3.23 g, 9.8 mmol). The resulting mixture was cooled to 0 °C before a 30% solution of H₂O₂ (30 mL, 294 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 30 min and at room temperature for 1 h. Then it was cooled to 0 °C and saturated aqueous NaHSO₃ (25 mL) was added slowly. The organic layer was separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were dried (NaSO₄), filtered and concentrated. The residue was purified by flash chromatography (*n*-hexane-EtOAc 2:1) to afford the sulfone as a colorless oil; yield: 14.35 g (93%). ¹H-NMR (300 MHz): δ 8.77-8.70 (m, 1H), 8.12-7.89 (m, 2H), 7.62-7.49 (m, 1H), 3.21 (s, 3H). ¹³C-NMR (75 MHz): δ 157.8, 149.9, 138.3, 127.4, 121.0, 39.9.

¹ Llamas, T; Arrayás, R. G.; Carretero, J. C. Angew. Chem. Int. Ed. 2007, 46, 3329-3332

General procedure for the synthesis of α,β -unsaturated sulfones (1a-1i): To a solution of 20 mmol of 2-(methylsulfonyl)pyridine (3.14 g) in dry THF (40 mL), cooled to -78 °C, was added a 1.6 M solution of *n*-BuLi in hexane (13.75 mL, 22 mmol, 1.1 eq). The mixture was stirred at -78 °C for 30 min followed by addition of the corresponding aldehyde (22 mmol, 1.1 eq.) at -78 °C and the reaction mixture was slowly warmed to room temperature. The reaction mixture was quenched with aqueous saturated NH₄Cl (25 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried with MgSO₄, filtered and concentrated in vacuo. Generally, the crude alcohol can be used without further purification for the next dehydration step. The crude alcohol (20 mmol) was dissolved in dry DCM (150 mL) under nitrogen atmosphere and DMAP (9.77 g, 80 mmol, 4 eq.) was added and the reaction mixture was cooled down to 0 °C. Subsequently, methanesulfonyl chloride (4.58 g, 40 mmol, 2 eg.) was added and the mixture was stirred while slowly warming to room temperature overnight. The reaction mixture was guenched with agueous saturated NH₄CI (100 mL). The layers were separated and the aqueous layer was extracted with DCM (3 x 50 mL). The combined organic layers were dried with MgSO₄, filtered and the solvent evaporated in vacuo. The crude product was purified by flash chromatography on silica gel to yield the α,β -unsaturated sulfone in moderate to good yield (31-75%).



(*E*)-2-(styrylsulfonyl)pyridine (1a)²: White solid, mp: 101.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.75 (br d, J = 4.7 Hz, 1H), 8.15 (dt, J= 7.7, 0.9 Hz, 1H), 7.96 (dt, J = 7.7, 7.7, 1.5 Hz, 1H), 7.79 (d, J = 15.5 Hz, 1H), 7.63-7.58 (m, 3H), 7.46 – 7.38 (m, 3H), 7.12 (d, J = 15.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 158.5, 150.4, 145.1, 138.2, 132.3, 131.4, 129.1, 128.8, 127.1, 124.5, 121.9. HRMS (EI+, *m/z*): calcd. for C₁₃H₁₁NO₂S [M]⁺: 245.0510; found: 245.0502. Anal. Calcd for C₁₃H₁₁NO₂S: C, 63.65; H, 4.52; N, 5.71; S, 13.04. Found: C, 63.43; H, 4.57; N, 5.50; S, 13.05.



² Desrosiers, J.–N.; Bechara, W. S.; Charette, A. B. Org. Lett., **2008**, 10, 2315-2318

(*E*)-2-(2-chlorostyrylsulfonyl)pyridine (1b): White solid. mp: 108 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, *J* = 4.6 Hz, 1H), 8.29-8.19 (m, 2H), 8.04 (td, *J* = 7.8, 1.6 Hz, 1H), 7.79-7.57 (m, 2H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.46-7.30 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 158.0, 150.2, 140.4, 138.2, 135.2, 132.0, 130.3, 130.2, 128.2, 127.2, 127.1, 121.7. HRMS (ESI+, *m/z*): calcd. for C₁₃H₁₁CINO₂S [M + H]⁺: 280.0193; found: 280.0186.



(*E*)-2-(3-chlorostyrylsulfonyl)pyridine (1c): White solid. mp: 92 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, *J* = 4.7 Hz, 1H), 8.07 (d, *J* = 7.8 Hz, 1H), 7.91 (td, *J* = 7.8, 1.7 Hz, 1H), 7.63 (d, *J* = 15.5 Hz, 1H), 7.48 (ddd, *J* = 7.6, 4.7, 0.9 Hz, 1H), 7.42-7.37 (m, 1H), 7.35-7.20 (m, 3H), 7.09 (d, *J* = 15.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 157.8, 150.2, 143.0, 138.2, 134.7, 133.8, 130.9, 130.2, 128.1, 127.2, 126.8, 126.0, 121.8. HRMS (ESI+, *m/z*): calcd. for C₁₃H₁₁CINO₂S [M + H]⁺: 280.0193; found: 280.0186.



(*E*)-2-(4-chlorostyrylsulfonyl)pyridine (1d): White solid. mp: 155.5-156.2 °C ¹H NMR (400 MHz, CDCl₃) δ 8.73 (ddd, *J* = 4. 7, 1.6, 0.8 Hz, 1H), 8.14 (td, *J* = 7.9, 1.0 Hz, 1H), 7.96 (dt, *J* = 7.8, 1.7 Hz, 1H), 7.72 (d, *J* = 15.5 Hz, 1H), 7.53 (ddd, *J* = 7.7, 4.7, 1.1 Hz, 1H), 7.48-7.44 (m, 2H), 7.39-7.35 (m, 2H), 7.09 (d, *J* = 15.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 158.3, 150.3, 143.5, 138.2, 137.4, 130.8, 129.8, 129.3, 127.1, 125.1, 121.8. HRMS (ESI+, *m/z*): calcd. for C₁₃H₁₁CINO₂S [M + H]⁺: 280.0193; found: 280.0192.



(*E*)-2-(4-methylstyrylsulfonyl)pyridine (1e): White solid. mp: 124 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 4.6 Hz, 1H), 8.12 (d, *J* = 7.8 Hz, 1H), 7.94 (m, 1H), 7.73 (d, *J* = 15.5 Hz, 1H), 7.54-7.47 (m, 1H), 7.40 (dd, *J* = 8.0, 1.2 Hz, 2H), 7.19 (d, *J* = 7.1 Hz, 2H), 7.04 (dd, *J* = 15.5, 2.0 Hz, 1H), 2.35 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 158.6, 150.3, 145.0, 142.0, 138.1, 129.7, 129.5, 128.7, 127.0, 123.3, 121.7, 21.5. HRMS (ESI+, *m/z*): calcd. for C₁₄H₁₄NO₂S [M + H]⁺: 260.0739; found: 260.0742.



(*E*)-2-(4-(trifluoromethyl)styrylsulfonyl)pyridine (1f)²: White solid. mp: 136.8-137.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 4.1 Hz, 1H), 8.10 (d, *J* = 7.8 Hz, 1H), 7.93 (m, 1H), 7.75 (d, *J* = 15.6 Hz, 1H), 7.59 (br s, 4H), 7.50 (dd, *J* = 7.6, 4.7 Hz, 1H), 7.21 (d, *J* = 15.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 157.8, 150.3, 142.8, 138.2, 135.5, 132.4 (q, *J*_{C-F} = 43.5 Hz), 128.8, 127.3, 127.3, 125.8 (q, *J*_{C-F} = 4.9 Hz), 123.4 (q, *J*_{C-F} = 361 Hz), 121.6. The physical and spectroscopic properties were in accordance with those described in literature.²



(*E*)-2-(4-isopropylstyrylsulfonyl)pyridine (1g): White solid. mp: 74 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 3.0 Hz, 1H), 8.13 (d, *J* = 7.8 Hz, 1H), 7.95 (m, 1H), 7.75 (d, *J* = 15.5 Hz, 1H), 7.51 (m, 1H), 7.45 (d, *J* = 8.2 Hz, 2H), 7.25 (d, *J* = 8.2 Hz, 2H), 7.06 (d, *J* = 15.5 Hz, 1H), 3.02-2.77 (m, 1H), 1.23 (d, *J* = 3.3 Hz, 3H), 1.21 (d, *J* = 3.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 158.5, 152.9, 150.3, 145.1, 138.1, 129.9, 128.8, 127.1, 127.0, 123.3, 121.7, 34.0, 23.6. HRMS (EI+, *m/z*): calcd. for C₁₆H₁₇NO₂S [M]⁺: 287.0980; found: 287.0988.



(*E*)-2-(4-bromostyrylsulfonyl)pyridine (1h): Orange solid. mp: 178 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (dd, *J* = 4.6, 0.8 Hz, 1H), 8.13 (dd, *J* = 7.9, 0.7 Hz, 1H), 7.95 (td, *J* = 7.8, 1.5 Hz, 1H), 7.70 (d, *J* = 15.5 Hz, 1H), 7.56-7.46 (m, 3H), 7.37 (d, *J* = 7.7 Hz, 2H), 7.11 (dd, *J* = 15.5, 1.3 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 158.2, 150.3, 143.6, 138.2, 132.3, 131.2, 130.0, 127.2, 125.8, 125.2, 121.9. HRMS (ESI+, *m/z*): calcd. for C₁₃H₁₁BrNO₂S [M + H]⁺: 323.9688; found: 323.9687.



(*E*)-2-(2-(naphthalen-2-yl)vinylsulfonyl)pyridine (1i)³: White solid. mp: 148 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.74 (m, 1H), 8.16 (br d, *J* = 7.9 Hz, 1H), 7.99-7.87 (m, 3H), 7.87-7.75 (m, 3H), 7.58 (br d, *J* = 8.6 Hz, 1H), 7.56-7.46 (m, 3H), 7.21 (d, *J* = 15.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 158.4, 150.3, 145.0, 138.2, 134.4, 132.3, 131.4, 129.6, 127.8, 127.7, 127.1, 127.0, 124.5, 123.5, 121.8. The physical and spectroscopic properties were in accordance with those described in literature.³

³ Mauleón, P.; Carretero, J. C. Org. Lett. **2004**, *6*, 3195

General procedure for the conjugate addition of diorganozinc reagents to α , β -unsaturated sulfones: Cu(OTf)₂ (6.6 mg, 18.3 μ mol, 7.3 mol%) and L1 (14.8 mg, 27.5 μ mol, 11 mol%) were dissolved in dry toluene (5.0 mL) under nitrogen atmosphere. The mixture was stirred for 30 min and cooled down to 0 °C and the diorganozinc reagent (3.2 eq) was added. After stirring for 15 min, the substrate (0.25 mmol, dissolved in 1.0 mL of toluene) was added over 3 h and the mixture was stirred for 24 h at 0 °C. Aqueous saturated NH₄Cl-solution (3 mL) was added and the mixture was warmed up to room temperature. The mixture was diluted with Et₂O and the layers were separated. The aqueous layer was extracted with DCM (3 x 10 mL) and the combined organic layers were dried with anhydrous Na₂SO₄, filtered and the solvent evaporated *in vacuo*. The crude material was purified by flash chromatography on silica to afford the pure product in moderate to good yield (46-86%).



(*S*)-(+)-2-(2-phenylbutylsulfonyl)pyridine (2a)¹: Colorless oil, yield: 70%. Enantiomeric excess: 91% determined by HPLC (Chiralcel AD 95:5 Heptane: *i*-PrOH: t_r (minor) 21.5 min, t_r (major) 23.8 min). [α]_D = +26.0 (*c* 2.4, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (dd, *J* = 4.5, 1.0 Hz, 1H), 7.72-7.66 (m, 2H), 7.39-7.32 (m, 1H), 7.11-7.00 (m, 3H), 6.99-6.95 (m, 2H), 3.95 (dd, *J* = 14.6, 8.6 Hz, 1H), 3.57 (dd, *J* = 14.6, 5.4 Hz, 1H), 3.21-3.12 (m, 1H), 1.93-1.81 (m, 1H), 1.64 (qdd, *J* = 14.2, 9.5, 7.3 Hz, 1H), 0.75 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.4, 149.9, 141.0, 137.7, 128.2, 127.8, 126.8, 126.7, 122.1, 57.5, 42.3, 29.5, 11.6. The physical and spectroscopic properties were in accordance with those described in literature.¹



(+)-2-(2-phenylhexylsulfonyl)pyridine (2c): Colorless oil, yield: 73%. Enantiomeric excess: 66% determined by HPLC (Chiralcel OD-H 90:10 Heptane: *i*-PrOH: t_r (minor) 26.7 min, t_r (major) 33.6 min). [α]_D = +53.8 (*c* 0.7, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.59-8.54 (m, 1H), 7.75-7.63 (m, 2H), 7.40-7.29 (m, 1H), 7.13-7.00 (m, 3H), 7.00-6.92 (m, 2H), 3.95 (dd, *J* = 14.6, 8.7 Hz, 1H), 3.56 (dd, *J* = 14.6, 5.4 Hz, 1H), 3.29 -3.19 (m, 1H), 1.91-1.71 (m, 1H), 1.71-1.54 (m, 1H), 1.37-0.95 (m, 4H), 0.80 (t, J = 7.2 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 157.5, 149.9, 141.4, 137.6, 128.3, 127.8, 126.7, 126.6, 122.1, 57.8, 40.6, 36.2, 29.1, 22.3, 13.8. HRMS (ESI+, m/z): calcd. for C₁₇H₂₁NO₂S [M + H]⁺: 304.13658; found: 304.13611.



(*S*)-(+)-2-(3-methyl-2-phenylbutylsulfonyl)pyridine (2d)³: White solid, yield: 61%. mp: 88 °C. Enantiomeric excess: 85% determined by HPLC (Chiralcel OD-H 92:8 Heptane: *i*-PrOH: t_r (minor) 33.8 min, t_r (major) 46.5 min). [α]_D = +24.2 (*c* 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.52 (ddd, *J* = 4.7, 1.6, 0.9 Hz, 1H), 7.57 (td, *J* = 7.6, 2.0 Hz, 1H), 7.51 (dt, *J* = 4.0, 1.2 Hz, 1H), 7.29 (ddd, *J* = 7.5, 4.7, 1.3 Hz, 1H), 7.00-6.93 (m, 3H), 6.90-6.84 (m, 2H), 4.07 (dd, *J* = 14.8, 10.8 Hz, 1H), 3.64 (dd, *J* = 14.8, 3.5 Hz, 1H), 3.00 (ddd, *J* = 10.9, 7.5, 3.5 Hz, 1H), 1.94-1.81 (m, 1H), 0.95 (d, *J* = 6.7 Hz, 3H), 0.70 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.2, 149.7, 139.5, 137.5, 128.7, 127.8, 126.5, 126.4, 122.2, 55.5, 47.4, 33.4, 20.6, 19.7. HRMS (ESI+, *m/z*): calcd. for C₁₆H₂₀NO₂S [M + H]⁺: 290.12093; found: 290.12062. The physical and spectroscopic properties were in accordance with those described in literature.³



(+)-2-(2-(2-chlorophenyl)butylsulfonyl)pyridine (3): Colorless oil, yield: 85%. Enantiomeric excess: 70% determined by HPLC (Chiralpak AD-H 90:10 Heptane: *i*-PrOH: t_r (minor) 30.3 min, t_r (major) 32.7 min). [α]_D = +30.7 (*c* 3.3, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (br d, *J* = 3.9 Hz, 1H), 7.86 (d, *J* = 7.7 Hz, 1H), 7.76 (m, 1H), 7.41-7.35 (m, 1H), 7.15 (br d, *J* = 7.7 Hz, 1H), 7.07-6.96 (m, 3H), 3.96 (dd, *J* = 14.1, 7.9 Hz, 1H), 3.77-3.66 (m, 1H), 3.66-3.55 (m, 1H), 1.98-1.85 (m, 1H), 1.78-1.63 (m, 1H), 0.76 (t, *J* = 7.3, Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.0, 149.9, 138.5, 137.7, 134.0, 129.6, 128.7, 127.8, 126.9, 126.8, 122.1, 56.3, 38.1, 28.6, 11.2. HRMS (ESI+, *m/z*): calcd. for C₁₅H₁₇CINO₂S [M + H]⁺: 310.0663; found: 310.0660.

S10



(+)-2-(2-(3-chlorophenyl)butylsulfonyl)pyridine (4): Colorless oil, yield: 66%. Enantiomeric excess: 84% determined by HPLC (Chiralpak AD-H 90:10 Heptane: *i*-PrOH: t_r (minor) 23.6 min, t_r (major) 27.4 min). [α]_D = +44.7 (*c* 2.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (dd, *J* = 4.6, 1.0 Hz, 1H), 7.74-7.66 (m, 2H), 7.39-7.33 (m, 1H), 7.04-6.94 (m, 2H), 6.92-6.85 (m, 2H), 4.01-3.91 (m, 1H), 3.51 (dd, *J* = 14.7, 4.0 Hz, 1H), 3.17-3.07 (m, 1H), 1.89-1.75 (m, 1H), 1.67-1.54 (m, 1H), 0.75 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.2, 149.8, 143.0, 137.5, 134.0, 129.5, 127.8, 126.9, 126.9, 126.3, 121.9, 57.0, 42.2, 29.4, 11.5. HRMS (ESI+, *m/z*): calcd. for C₁₅H₁₇CINO₂S [M + H]⁺: 310.0663; found: 310.0649.



(+)-2-(2-(4-chlorophenyl)butylsulfonyl)pyridine (5): White solid, yield: 68%. mp: 81 °C. Enantiomeric excess: 89% determined by HPLC (Chiralpak AD-H 90:10 Heptane: *i*-PrOH: t_r (minor) 29.3 min, t_r (major) 31.6 min). [α]_D = +41.2 (*c* 2.6, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.57-8.54 (m, 1H), 7.74-7.68 (m, 1H), 7.67-7.63 (m, 1H), 7.42-7.36 (m, 1H), 7.01 (d, *J* = 8.4 Hz, 2H), 6.90 (d, *J* = 8.3 Hz, 2H), 3.93 (dd, *J* = 14.7, 9.3 Hz, 1H), 3.54 (dd, *J* = 14.7, 4.9 Hz, 1H), 3.14 (ddd, *J* = 14.6, 9.7, 5.1 Hz, 1H), 1.89-1.75 (m, 1H), 1.59 (qdd, *J* = 14.4, 9.7, 7.4 Hz, 1H), 0.74 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.2, 149.8, 139.4, 137.7, 132.3, 129.2, 128.2, 126.7, 122.0, 57.3, 41.8, 29.3, 11.5. HRMS (ESI+, *m/z*): calcd. for C₁₅H₁₇CINO₂S [M + H]⁺: 310.0663; found: 310.0663.



(+)-2-(2-*p*-tolylbutylsulfonyl)pyridine (6): Colorless oil, yield: 46%. Enantiomeric excess: 92% determined by HPLC (Chiralpak AD-H 90:10 Heptane: *i*-PrOH: t_r (minor) 24.6 min, t_r (major) 28.0 min). [α]_D = +34.4 (*c* 1.2,

CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (br d, *J* = 4.6 Hz, 1H), 7.68 (br d, *J* = 3.7 Hz, 2H), 7.40-7.33 (m, 1H), 6.86 (br s, 4H), 3.91 (dd, *J* = 14.6, 8.6 Hz, 1H), 3.56 (dd, *J* = 14.6, 5.5 Hz, 1H), 3.17-3.07 (m, 1H), 2.20 (s, 3H), 1.91-1.79 (m, 1H), 1.68-1.55 (m, 1H), 0.75 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.4, 149.8, 138.0, 137.5, 136.1, 128.9, 127.7, 126.5, 122.1, 57.7, 41.9, 29.3, 20.8, 11.6. HRMS (ESI+, *m*/*z*): calcd. for C₁₆H₂₀NO₂S [M + H]⁺: 290.1209; found: 290.1206.



(S)-(+)-2-(2-(4-trifluoromethyl)phenyl)butylsulfonyl)pyridine (7)²: Yellow oil, yield: 84%. Enantiomeric excess: 96% determined by HPLC (Chiralpak AD-H 90:10 Heptane: *i*-PrOH: t_r (minor) 23.5 min, t_r (major) 24.8 min). [α]_D = +37.0 (*c* 3.6, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 4.6 Hz, 1H), 7.69-7.60 (m, 2H), 7.37-7.32 (m, 1H), 7.30 (br d, *J* = 7.9 Hz, 2H), 7.09 (d, *J* = 7.9 Hz, 2H), 4.02 (dd, *J* = 14.7, 9.6 Hz, 1H), 3.57 (dd, *J* = 14.8, 4.6 Hz, 1H), 3.29-3.19 (m, 1H), 1.93-1.80 (m, 1H), 1.73-1.59 (m, 1H), 0.77 (dt, *J* = 7.3, 1.9 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.2, 149.9, 145.0, 137.7, 128.9 (q, *J*_{C-F} = 32.5 Hz), 128.3, 126.8, 125.0 (q, *J*_{C-F} = 3.8 Hz), 123.9 (q, *J*_{C-F} = 273.0 Hz), 122.0, 57.0, 42.4, 29.4, 11.5. The physical and spectroscopic properties were in accordance with those described in literature.²



(+)-2-(2-(4-isopropylphenyl)butylsulfonyl)pyridine (8): Colorless oil, yield: 52%. Enantiomeric excess: 90% determined by HPLC (Chiralcel OD 95:5 Heptane: *i*-PrOH: t_r (minor) 26.5 min, t_r (major) 32.9 min). [α]_D = +43.0 (*c* 2.1, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 3.7 Hz, 1H), 7.69-7.61 (m, 2H), 7.35-7.29 (m, 1H), 6.88 (m, 4H), 3.98 (dd, *J* = 14.7, 8.9 Hz, 1H), 3.53 (dd, *J* = 14.7, 5.2 Hz, 1H), 3.19-3.08 (m, 1H), 2.81-2.69 (m, 1H), 1.90-1.78 (m, 1H), 1.68-1.55 (m, 1H), 1.15 (d, *J* = 6.9 Hz, 6H), 0.76 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.4, 149.8, 147.0, 138.2, 137.5, 127.7, 126.6, 126.2, 122.1, 57.6, 42.0, 33.5, 29.5, 24.0, 23.9, 11.6. HRMS (EI+, *m/z*): calcd. for C₁₆H₁₈NO₂S [M - C₂H₅]⁺: 288.1058; found: 288.1065.



(+)-2-(2-(4-bromophenyl)butylsulfonyl)pyridine (9): White solid, yield: 86%. mp: 82.9 °C. Enantiomeric excess: 96% determined by HPLC (Chiralcel OD 95:5 Heptane: *i*-PrOH: t_r (minor) 24.4 min, t_r (major) 33.0 min). [α]_D = +45.0 (*c* 3.8, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.56 (br d, *J* = 4.1 Hz, 1H), 7.72 (dt, *J* = 7.7, 1.6 Hz, 1H), 7.64 (br d, *J* = 7.8 Hz, 1H), 7.40 (ddd, *J* = 7.5, 4.7, 1.1 Hz, 1H), 7.16 (br d, *J* = 8.4 Hz, 2H), 6.84 (br d, *J* = 8.4 Hz, 2H), 3.94 (dd, *J* = 14.7, 9.4 Hz, 1H), 3.54 (dd, *J* = 14.7, 4.9 Hz, 1H), 3.19-3.08 (m, 1H), 1.89-1.76 (m, 1H), 1.66-1.53 (m, 1H), 0.75 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.3, 149.9, 140.0, 137.7, 131.2, 129.7, 126.7, 122.0, 120.5, 57.3, 42.0, 29.3, 11.5. HRMS (ESI+, *m*/*z*): calcd. for C₁₅H₁₇BrNO₂S [M + H]⁺: 354.0158; found: 354.0152.



(S)-(+)-2-(2-(naphthalen-2-yl)butylsulfonyl)pyridine (10): White solid, yield: 83%. mp: 105 °C. Enantiomeric excess: 93% determined by HPLC (Chiralcel OD 95:5 Heptane: *i*-PrOH: t_r (minor) 26.5 min, t_r (major) 32.9 min). [α]_D = +55.0 (*c* 3.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 8.43-8.40 (m, 1H), 7.70-7.60 (m, 2H), 7.52 (dt, *J* = 8.2, 0.8 Hz, 2H), 7.44-7.37 (m, 3H), 7.31-7.26 (m, 1H), 7.09 (dd, *J* = 8.5, 1.7 Hz, 1H), 7.05-7.01 (m, 1H), 4.10 (dd, *J* = 14.7, 9.4 Hz, 1H), 3.61 (dd, *J* = 14.7, 4.9 Hz, 1H), 3.34 (tt, *J* = 9.7, 5.0 Hz, 1H), 2.00-1.87 (m, 1H), 1.83-1.68 (m, 1H), 0.80 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 157.0, 149.5, 137.9, 136.9, 132.8, 132.1, 127.9, 127.3, 127.2, 127.0, 126.1, 125.8, 125.5, 125.2, 121.8, 57.5, 42.5, 29.3, 11.5. The physical and spectroscopic properties were in accordance with those described in literature.² NMR Spectra of new compounds

S14



S15 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S16
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S17 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S18
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S19 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S20
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S21
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY





S23 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S24
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S25
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S26
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY







S29
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY





S31 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S32 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S33
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S34 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S35 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S36
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S37 PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S38
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY



S39
PRIVILEGED DOCUMENT FOR REVIEW PURPOSES ONLY

